Benitec Biopharma Files 8-K: Material Agreement & Financials

Ticker: BNTC · Form: 8-K · Filed: Oct 11, 2024 · CIK: 1808898

Benitec Biopharma INC. 8-K Filing Summary
FieldDetail
CompanyBenitec Biopharma INC. (BNTC)
Form Type8-K
Filed DateOct 11, 2024
Risk Levelmedium
Pages3
Reading Time3 min
Key Dollar Amounts$0.0001 B, $0.0001, $75 million
Sentimentneutral

Sentiment: neutral

Topics: material-agreement, financials

TL;DR

Benitec Biopharma signed a big deal and filed financials on Oct 11.

AI Summary

On October 11, 2024, Benitec Biopharma Inc. filed an 8-K report. The filing indicates the company entered into a Material Definitive Agreement and also includes financial statements and exhibits. Specific details of the agreement or financial figures were not provided in the excerpt.

Why It Matters

This filing signals a significant development for Benitec Biopharma, potentially involving new partnerships, funding, or strategic shifts, which could impact its future operations and stock performance.

Risk Assessment

Risk Level: medium — The filing indicates a material definitive agreement, which could be positive or negative depending on its terms, and the inclusion of financial statements suggests potential financial events.

Key Players & Entities

FAQ

What is the nature of the Material Definitive Agreement Benitec Biopharma entered into?

The provided excerpt does not specify the details of the Material Definitive Agreement.

When was the 8-K report filed?

The 8-K report was filed on October 11, 2024.

What are the principal executive offices of Benitec Biopharma Inc.?

The principal executive offices are located at 3940 Trust Way, Hayward, California, 94545.

What is Benitec Biopharma Inc.'s IRS Employer Identification No.?

The IRS Employer Identification No. is 84-4620206.

What is the SIC code for Benitec Biopharma Inc.?

The Standard Industrial Classification code is 2834, Pharmaceutical Preparations.

Filing Stats: 806 words · 3 min read · ~3 pages · Grade level 11.5 · Accepted 2024-10-11 16:52:01

Key Financial Figures

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BENITEC BIOPHARMA INC. (Registrant) By: /s/ Jerel A. Banks Date: October 11, 2024 Jerel A. Banks Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing